Ken, very clear-eyed perspective on this story, and you

New Post Public Reply Private Reply Replies (0) Message Board
MGK_2 KenChowder #165277
296
Ken, very clear-eyed perspective on this story, and you have put your finger on a distinction many miss.

First the calendar. You have the dates right, ASCO GI runs January 21 to 23, 2027, at Moscone West in San Francisco. (ASCO GI 2027, Jan 21-23, San Francisco) And your read on the embargo rhythm is correct, the abstract publishes a few days ahead of the live session, which is the moment the pre-meeting embargo lifts and we finally see numbers that, by then, are already old.

Now the distinction you drew, which is the valuable one, An ASCO abstract is a snapshot frozen at a submission cutoff, and for this meeting that cutoff is roughly late September. So what we read in January is a photograph of how CLOVER looked in the early fall, not how it looks the day we read it. For most trials that gap is a footnote. For this one it is the whole story. CLOVER’s signal has been maturing in the direction of more responses, investigator-assessed partial responses waiting on confirmation, ctDNA deepening, the rollover arm accruing. A dataset that is still ripening does not sit still across four months. So the abstract is likely to understate where the trial actually stands by the time it is presented, because it reports the fall and the drug has kept working through the winter. You are right to look past the abstract to the near-final data that lands just after it. The abstract is the trailer. The data is the film.

The open-label observation is the one that ties it together. In principle, an open-label trial could let news flow continuously, there is no blind to lift. In practice, the company has chosen to let the conference calendar govern disclosure, which is why our knowledge has run months behind the reality the entire way. That is not a complaint, it is disciplined, you hold data for the venue that gives it the most weight. But it does mean the gap between what is known inside the company and what we outside can see has been real and persistent. Which brings us to your last point.

On Wilcoxen, you and I are reading the same tea leaves and reaching the same place. The thing that makes her signing meaningful is exactly the gap you just described. She is not reacting to the fall snapshot the rest of us will get in January. She has been inside, with current access, watching the film as it develops, and she left a secure NASDAQ role to commit on the strength of what she has seen to this minute. That is the cleanest version of an insider-conviction signal, someone with everything to lose, full and current information, and a choice to buy in anyway. 
I would hold one piece of discipline on it, her knowing is not the same as our knowing, and it is a read on her confidence, not a disclosure of the numbers. But as indirect evidence goes, it is close to the best kind there is, because she is betting her career on data we will not see in full until weeks after she already acted on it. Supremely good indication is the right phrase. Well said, Ken, and I cannot wait either.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 114

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 99

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 0

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 52

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 305

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 319

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 24

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Racura's AML Trial Clears Its First Crucial Hurdle

Updated Category News Views 13

One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 225

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading

Top 5 Most Recently Viewed Articles

AEA Private Debt's Strategic Investment in Weller Metalworks

Updated Category News Views 299

Let's cut to the chase: AEA Private Debt is making some serious waves in the middle market with its latest move as the Sole Provider of mezzanine notes for Weller Metalworks' acquisition of DROP Sprockets, Inc. This isn’t just another deal; it’s a calculated step in an increasingly competitive landscape where metal fabrication firms are vying for supremacy. Weller...

Continue Reading
Medication Management Partners Continues to Excel in Senior Care

Updated Category News Views 196

Medication Management Partners Earns Prestigious Recognition In recent news, Medication Management Partners (MMP), a leading long-term care pharmacy, proudly announces its place on the Inc. 5000 list of fastest-growing private companies in America for the seventh consecutive year. This achievement signifies the company’s steady growth and innovative practices in the...

Continue Reading
AlphaGen Unveils Major Expansion Plans for Power Generation

Updated Category News Views 501

AlphaGen's Ambitious 450 MW Power Generation Initiative Alpha Generation, LLC ("AlphaGen"), based in Stamford, Conn., is taking a significant step towards meeting the escalating demand for reliable electric power across the nation. With plans to add approximately 450 megawatts (MW) of additional electric generation at four existing power stations, AlphaGen aims to bolster...

Continue Reading
STAT Secures a Loeb Award for Outstanding Reporting on Opioids

Updated Category News Views 185

STAT Achieves Recognition for Vital Reporting STAT addiction reporter Lev Facher has been honored with a 2025 Loeb Award for his exceptional work in explanatory reporting. This award, regarded as the pinnacle of accomplishment in business and financial journalism, recognizes Facher's six-part series titled "The War on Recovery." The compelling series sheds light on the...

Continue Reading
Investigation into Nomura Holdings, Inc. Sparks Investor Concerns

Updated Category News Views 67

Introduction to the Investigation of Nomura Holdings, Inc. Pomerantz LLP is currently conducting an investigation focused on claims made on behalf of investors of Nomura Holdings, Inc. (NYSE: NMR). The essence of this investigation revolves around whether Nomura and some of its key officers or directors may have engaged in securities fraud or other illicit business...

Continue Reading